When to Order Imaging for Staging and Follow-up of Esophageal Cancer: ACR Appropriateness Decoded

When to Order Imaging for Staging and Follow-up of Esophageal Cancer: ACR Appropriateness Decoded

A patient presents with dysphagia and weight loss, and an endoscopy confirms a new diagnosis of esophageal cancer. The next critical step is accurate staging to determine the optimal treatment strategy, which could range from endoscopic resection to neoadjuvant chemoradiation followed by surgery. Choosing the right initial imaging modality—and the correct follow-up studies—is essential for patient outcomes. Deciding between a contrast-enhanced computed tomography (CT) scan, a positron emission tomography (PET)/CT, or another modality can be complex. This guide clarifies the American College of Radiology (ACR) Appropriateness Criteria for imaging esophageal cancer, providing evidence-based recommendations to support your clinical decisions.

What Does ACR Staging and Follow-up of Esophageal Cancer Cover?

This ACR guideline focuses on the use of diagnostic imaging for the initial staging, treatment response assessment, and post-treatment surveillance of patients with a confirmed diagnosis of esophageal cancer. The criteria are designed to guide imaging choices for both squamous cell carcinoma and adenocarcinoma of the esophagus. The recommendations address four primary clinical phases: initial pretreatment staging, imaging during active treatment, routine post-treatment surveillance in asymptomatic patients, and evaluation for suspected or known recurrence.

These criteria do not cover the initial diagnosis of esophageal cancer, which is typically made via endoscopy and biopsy. They also do not address screening for esophageal cancer in high-risk populations (e.g., patients with Barrett’s esophagus) or the specific imaging protocols for guiding interventional procedures like radiation therapy planning, though the recommended studies are foundational for such planning.

What Imaging Should I Order for Staging and Follow-up of Esophageal Cancer? Recommendations by Clinical Scenario

The appropriate imaging for esophageal cancer depends entirely on the clinical context. The ACR provides specific guidance for each stage of the patient’s journey, from initial workup to long-term follow-up.

For a newly diagnosed esophageal cancer requiring pretreatment clinical staging, both FDG-PET/CT from the skull base to mid-thigh and CT of the chest and abdomen with IV contrast are rated Usually appropriate. PET/CT is highly sensitive for detecting regional lymph node involvement and distant metastatic disease, which fundamentally alters treatment planning. Contrast-enhanced CT is excellent for evaluating the extent of the primary tumor, its relationship to adjacent structures, and detecting liver or lung metastases. The choice between them often depends on institutional availability and multidisciplinary tumor board consensus. A CT Chest/Abdomen/Pelvis with IV Contrast is rated May be appropriate (Disagreement), reflecting variability in practice for including the pelvis in the initial scan.

During treatment, imaging is used to assess therapeutic response. For esophageal cancer imaging during treatment, FDG-PET/CT is again rated Usually appropriate. A decrease in FDG avidity can be an early indicator of response to neoadjuvant chemotherapy or chemoradiation, potentially guiding subsequent management. In this context, CT alone is considered Usually not appropriate as it is less sensitive for assessing metabolic response compared to PET/CT.

For routine posttreatment imaging with no suspected or known recurrence, both CT of the chest and abdomen with IV contrast and FDG-PET/CT are rated Usually appropriate. CT is often used for routine surveillance to detect anatomical changes suggestive of recurrence. PET/CT may be preferred in certain high-risk situations or if CT findings are equivocal, as it can detect metabolically active recurrence before significant structural changes are visible.

Finally, in the setting of posttreatment imaging for suspected or known recurrence, the recommendations mirror those for initial staging. Both FDG-PET/CT and CT of the chest and abdomen with IV contrast are Usually appropriate. These studies are essential for confirming the location and extent of recurrent disease to guide salvage therapy, whether it be surgery, radiation, or systemic treatment.

ACR Imaging Recommendations Table

Adult vs. Pediatric Staging and Follow-up of Esophageal Cancer Imaging: Radiation Dose Tradeoffs

Esophageal cancer is exceedingly rare in the pediatric population. However, the principles of radiation safety and the As Low As Reasonably Achievable (ALARA) concept are paramount when imaging is required in younger patients for any condition. The ACR provides distinct pediatric relative radiation level (RRL) estimates for several modalities, reflecting the heightened concern for the long-term risks of ionizing radiation in children and adolescents, such as the potential for secondary malignancies.

For example, while an adult FDG-PET/CT carries an RRL of ☢ ☢ ☢ ☢ (10-30 mSv), the pediatric equivalent is also rated ☢ ☢ ☢ ☢ but corresponds to a lower dose range of 3-10 mSv. This difference underscores the use of dose-reduction techniques and weight-based radiotracer dosing that are standard in pediatric nuclear medicine. For any imaging involving radiation, the clinical question must justify the exposure. In the rare instance of esophageal cancer in a pediatric patient, a multidisciplinary discussion involving pediatric oncologists, surgeons, and radiologists is critical to ensure that the most appropriate, lowest-dose imaging protocol is selected to stage disease and monitor treatment response effectively.

Imaging Protocol Details for Staging and Follow-up of Esophageal Cancer

Once you’ve decided on the right study, the specific imaging protocol is critical for obtaining high-quality, diagnostic images. Details such as the timing of IV contrast, the field of view, and reconstruction parameters can significantly impact diagnostic accuracy. Our protocol guides provide detailed, scannable instructions for the key studies recommended in this guideline.

• CT Chest/Abdomen/Pelvis with IV Contrast

Tools to Help You Order the Right Study

Selecting the optimal imaging study from a long list of possibilities can be challenging. GigHz offers a suite of tools designed to streamline this process, ensuring your orders are evidence-based and appropriate for the clinical scenario.

For clinical questions beyond esophageal cancer, the ACR Appropriateness Criteria Lookup provides a comprehensive, searchable interface to find the right study for thousands of clinical variants. To ensure the selected study is performed correctly, the Imaging Protocol Library offers detailed, step-by-step protocols for a wide range of CT, MRI, and ultrasound examinations. Finally, to help manage and communicate radiation exposure with patients, the Radiation Dose Calculator allows for estimating cumulative effective dose from various imaging studies.

Why is FDG-PET/CT so important for staging esophageal cancer?

FDG-PET/CT is crucial because it combines functional information (metabolic activity) with anatomical information (CT). It is more sensitive than CT alone for detecting regional lymph node metastases and distant metastases, particularly in non-enlarged lymph nodes or small metastatic deposits in the liver, bone, or other organs. Identifying distant disease (M1) upstages the patient and often changes the treatment plan from curative-intent local therapy (surgery/radiation) to palliative systemic therapy.

Is an upper GI series (barium esophagram) ever appropriate?

According to the ACR criteria for staging and follow-up, a fluoroscopy upper GI series is rated Usually not appropriate. While an esophagram can be useful in the initial diagnostic workup of dysphagia to identify a stricture or mass, it does not provide the detailed information needed for staging. It cannot assess the depth of tumor invasion, lymph node status, or distant metastases, which are all critical for treatment planning and are better evaluated by CT and PET/CT.

What is the role of MRI in staging esophageal cancer?

MRI of the chest and abdomen is generally rated as May be appropriate or Usually not appropriate for esophageal cancer staging. While MRI offers excellent soft tissue contrast, it is more susceptible to motion artifact from breathing and peristalsis, which can limit its utility in evaluating the esophagus. Its primary role may be as a problem-solving tool, particularly for assessing liver metastases if they are indeterminate on CT or for patients who have a severe contraindication to iodinated CT contrast.

When should I extend a CT of the chest and abdomen to include the pelvis?

The ACR panel notes disagreement on this point for initial staging, rating a CT of the chest, abdomen, and pelvis with IV contrast as May be appropriate (Disagreement). The decision to include the pelvis depends on the clinical suspicion for metastatic disease below the standard abdominal field of view. PET/CT, which typically covers from the skull base to the mid-thigh, inherently includes the pelvis and is often preferred for comprehensive staging. If PET/CT is not available, extending the CT to the pelvis may be considered to screen for osseous or other pelvic metastases.

Why isn’t CT recommended for monitoring response during treatment?

For assessing response during neoadjuvant therapy, CT is rated Usually not appropriate. The primary reason is that changes in tumor size on CT (anatomic response) lag behind changes in tumor metabolism (metabolic response). FDG-PET/CT can show a significant decrease in glucose uptake early in the treatment course, providing a more timely and sensitive indicator of treatment efficacy. This information can help determine if the current therapy is working or if a change in strategy is needed.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026